However, a recent prospective study performed in 10 adults with cabergoline-resistant prolactinoma, in which metformin (1.0–2.5 g/d) was added to cabergoline, failed to show a consistent inhibitory effect in serum prolactin levels; unfortunately, tumour volume changes were not reported [90]. The gene discussed is PRL; the disease is neoplasm.